Sulzberger Gabrielle has demonstrated a consistent buying pattern in Eli Lilly and Company (LLY) shares, with no recorded sales across 24 transactions totaling $634,158.62 since January 2024. The activity reveals a disciplined accumulation strategy, with most purchases falling in the $4,958 range—likely representing automated or scheduled acquisitions. Two notable exceptions include a $219,999.6 buy on November 17, 2025, and a $75,018.29 acquisition on August 12, 2025, marked as a derivative transaction (Code P). Recent filings show sustained monthly investments, with identical $4,958.46 purchases on March 16, 2026, following similar transactions in February and January 2026.
The trades suggest a long-term position-building approach concentrated solely in LLY, with no diversification across other securities. Early 2024 transactions showed slightly higher variability in amounts ($9,823.58 to $10,153.12), later standardizing to the ~$4,958 pattern. The absence of any sell transactions—coupled with the repetition of buy codes (A for open market or P for derivative)—indicates unwavering directional confidence in the pharmaceutical stock. While the exact nature of Sulzberger’s relationship to Eli Lilly remains unspecified in SEC filings, the transactional rhythm points to either systematic investing or compensation-linked equity accumulation.
AI-assisted summary